Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction

Clinical Cardiology

Volumn 25, Issue 11 SUPPL. 1, 2002, Pages

  Ferguson, James J ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

Acute coronary syndrome; Aspirin; Pentasaccharide; Platelet glycoprotein IIb IIIa inhibitors; Thienopyridines; Thrombin inhibitors; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; PYRIDINE DERIVATIVE; TENECTEPLASE; THIENO[2,3 B]PYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART CATHETERIZATION; HEART INFARCTION; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; REBOUND; RESTENOSIS; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0036829061     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960251305     Document Type: Review

References (43)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Théroux P: ACC/AHA Guideline Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf., 2002
2. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chester E, De Mots H: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403
3. Calms JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG: Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-1375
4. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111
5. RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830
6. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorck I, Fox KA, Chesebro J II, Strain J, Keller C, for the Antithrombotic Therapy in Acute Coronary Syndromes Research Group: Combination anfithrombotic therapy in unstable rest angina and non-Q wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial. Circulation 1994;89:81-88
7. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B: Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia., J Am Coll Cardiol 1995;26:313-318
8. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J. Olaisson E, Undeland S, Ludwig K: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-68
9. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-1562
10. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA. Premmereur J, Bigonzi F: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452
11. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bemink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) IIB trial. Circulation 1999;100:1593-1601
12. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI IIB-ESSENCE meta-analysis. Circulation 1999;100:1602-1608
13. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568
14. FRagmin and Fast Revascularization during InStability in Coronary artery disease Investigators: Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancer 1999;354:701-707
15. Papamichael ND, Michalis LK, Katsouras CS, Adamidis K, Souria E, Sioros L, Papalambrakakoupoulos A, Goudevenos JA, Sideris DA, Novas J: Enoxaparin versus tinzaparin in unstable coronary syndromes. A head-to-head comparison (EVET trial) (abstr). Eur Heart J 2001;22:664
16. Cohen M, Théroux P, Weber S, Laramee P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD: Combinations therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-281
17. Cohen M, Théroux P, Frey MJ, White HD, Borzak S, Weber S, Senatore F, Espenshade M, Mukherjee R, Thornton A, Bigonzi F, Sax FL: Anti-thrombotic combination using tirofiban and enoxaparin: The ACUTE II Study (abstr). Circulation 2000;102:11-826
18. Kaul S, Shah PK: Low-molecular-weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000;35: 1699-1712
19. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S: Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000;355:1936-1942
20. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443
21. PRISM-PLUS study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQ wave myocardial infarction. N Engl J Med 1998;338:1488-1497
22. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349: 2429-2435
23. GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomized trial. Lancet 2001;357:1915-1924
24. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
25. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358: 527-533
26. OASIS Investigators: Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia with ST elevation: A pilot study. Circulation 1997;96:769-777
27. OASIS Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial. Lancet 1999;353:429-438
28. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637
29. The GUSTO Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med 1996;335:775-782
30. The Direct Thombin Inhibitor Trialists' Collaborative Group: Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients data. Lancet 2002:359:294-302
31. Simoons ML: Hot Line Session Oral Presentation, AHA 2001
32. Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB: Low-molecular-weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908-914
33. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low-molecular-weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol 1996;28:1437-1443
34. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13: 272-278
35. Ferguson JJ: Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invas Cardiol 2000;12:E 10-13
36. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Théroux P, the Nice 3 Investigators: The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study (abstr). J Am Coll Cardiol 2001;37:Suppl A:1A-648A
37. Galeote G, Hussein M, Sobrino N, Calvo L, Yunda H, Sánchez-Recalde A, Sobrino JA: Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: A randomized study (abstr). Eur Heart J 2001;22:663
38. Bhatt DL, Lincoff AM: Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: The results of the CRUISE trial. Circulation 2001;104:11-384-385
39. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, Van de Werf F: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE - Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002; 105:1642-1649
40. Goodman SG: Hot Line Session Oral Presentation, ACC 2002 41.
41. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D: Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663
42. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D: Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663
43. Martin JL, Fry ETA, Serano A, Atherley TH, Ozoux MI, Gulmart C, Chevalier P, Bigonzi F, Pensyl C, Sanderink GJ: Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: The PEPCI study (abstr). Eur Heart J 2001;22:14